关于冠心病二级预防的思考被引量：5

导出

摘要目的了解冠心病患者二级预防的现状,特别关注阿司匹林应用方面。方法以1380例既往曾确诊患有冠心病的门诊患者为研究对象,采用访谈形式收集患者信息,填写统一表格。结果(1)在1380例门诊冠心病患者中,男765例,女615例,年龄50～75岁。(2)门诊冠心病患者阿司匹林服用率为82.6%,其中男性86.1%高于女性81.2%。随着年龄的增加,阿司匹林的服用率呈下降趋势。(3)门诊冠心病患者阿司匹林的处方率为91.4%,总计92.6%的医生处方剂量符合《阿司匹林在动脉硬化性心血管疾病中临床应用:中国专家共识(2005)》[1]中建议使用的剂量。个别医生的处方剂量低于75mg/d。结论目前门诊冠心病患者二级预防中阿司匹林的总服用率为82.6%,但服药的依从性随年龄增长存在差异,医生阿司匹林处方剂量间也存在差异,应在冠心病二级预防中引起足够重视。

作者张优佳

机构地区山东省滨州市滨城区市立医院

出处《中国现代药物应用》 2013年第2期134-135,共2页 Chinese Journal of Modern Drug Application

关键词冠心病二级预防阿司匹林处方

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献1

1李小鹰.阿司匹林在动脉硬化性心血管疾病中的临床应用:中国专家共识(2005)[J].中华心血管病杂志,2006,34(3):281-284. 被引量：194

二级参考文献17

1Patrono C,Bachmann F,Baigent C,et al.European Society of Cardiology.Expert consensus document on the use of antiplatelet agents.The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology.Eur Heart J,2004,25:166-181.
2Eagle KA,Guyton RA,Davidoff R,et al.American College of Cardiology.American Heart Association Task Force on Practice Guidelines.American Society for Thoracic Surgery and the Society of Thoracic Surgeons.ACC/AHA 2004 guideline update for coronary artery bypass graft surgery:summary article:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery).Circulation,2004,110:1168-1176.
3Stein PD,Alpert JS,Bussey HI,et al.Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves.Chest,2001,119:2205-2275.
4Chen ZM,Jiang LX,Chen YP,et al.COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group.Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction:randomised placebo-controlled trial.Lancet,2005,366:1607-1621.
5Patrono C,Coller B,FitzGerald GA,et al.Platelet-active drugs:the relationships among dose,effectiveness,and side effects:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Chest,2004,126(3 Suppl):234S-264S.
6Pearson TA,Blair SN,Daniels SR,et al.AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke:2002 Update:Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases.American Heart Association Science Advisory and Coordinating Committee.Circulation,2002,106:388-391.
7Ridker PM,Cook NR,Lee IM,et al.A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.N Engl J Med,2005,352:1293-1304.
8Antithrombotic Trialists' Collaboration.Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death,myocardial infarction,and stroke in high risk patients.BMJ,2002,324:71-86.
9Yusuf S,Zhao F,Mehta SR,et al.Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.N Engl J Med,2001,345:494-502.
10Juul-Moller S,Edvardsson N,Jahnmatz B,et al.Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris.Lancet,1992,340:1421-1425.